77
Participants
Start Date
November 19, 2018
Primary Completion Date
September 13, 2021
Study Completion Date
March 23, 2022
Guselkumab
Guselkumab SC will be administered every 4 weeks.
Placebo
Placebo SC will be administered every 4 weeks.
Hosp Univ Vall D Hebron, Barcelona
Hosp Clinic de Barcelona, Barcelona
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York
APHM Hopital Timone, Marseille
University of Pennsylvania - Perelman School of Medicine, Philadelphia
Fox Chase Cancer Center, Philadelphia
Mayo Clinic Jacksonville, Jacksonville
University of Miami, Miami
University of South Florida, Tampa
Wexner Medical Center at the Ohio State University, Columbus
Cleveland Clinic, Cleveland
Universitatsklinikum Bonn, Bonn
Washington University School Of Medicine, St Louis
Sourasky MC, Tel Aviv
Hopital Edouard Herriot - CHU Lyon, Lyon
Ochsner Medical Center, New Orleans
University of Texas MD Anderson Cancer Center, Houston
University of Utah Huntsman Cancer Institute, Salt Lake City
Mayo Clinic, Phoenix
Universitatsklinikum Ulm, Ulm
City of Hope, Duarte
University of Washington, Seattle
Yale University, New Haven
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam
Leiden University Medical Center, Leiden
Erasmus MC, Rotterdam
Szpital Kliniczny im Heliodora Swiecickiego Uniwersytetu Medycznego im Karola Marcinkowskiego w Po, Poznan
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Pan American Center for Oncology Trials LLC, Rio Piedras
Karolinska Universitetssjukhuset, Stockholm
Janssen Research & Development, LLC
INDUSTRY